Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Post by scarlet1967on Sep 29, 2021 9:29am
120 Views
Post# 33936047

More research

More research

Single-cell and bulk transcriptomics of the liver reveals potential targets of NASH with fibrosis - Scientific Reports

Single-cell and bulk transcriptomics of the liver reveals potential targets of NASH with fibrosis - Scientific Reports

 

https://www.practiceupdate.com/content/nafld-glycemic-control-predicts-severity-of-hepatocyte-ballooning-and-fibrosis/123967/37/9/1

Dr. Grinspoon during the KOL event was referring to therapeutic effect by Tesamorelin on glucose levels in blood and both Dr. Grinspoon and Dr. Stanley have studied the Transcriptomic effect of the drug on NASH patients. Yet again these two articles are addressing the same issues and their role of them in the condition.

There has been a shift towards understanding the condition and how to find a treatment for it which is very similar to Tesamorelin’s mechanism of action.

<< Previous
Bullboard Posts
Next >>